Evidence map›Paper›PMID 31171876›Full record

ArticleNature medicine2019

Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.

Ryan J Sullivan, Omid Hamid, Rene Gonzalez, Jeffrey R Infante, Manish R Patel, F Stephen Hodi, Karl D Lewis, Hussein A Tawbi, Genevive Hernandez, Matthew J Wongchenko and 6 more

Abstract readClinical Trial, Phase IMulticenter Study
PubMed Publisher
In one paragraph

Article in Nature medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 141 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
141citing papers in PubMed, 7 pooled it
14.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

141 citing papers in PubMed, 7 syntheses or guidelines pooled it, 234 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib inJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2020
    Trial
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

81 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Ryan J SullivanMassachusetts General Hospital Cancer Center, Boston, MA, USA. rsullivan7@mgh.harvard.edu.ORCID http://orcid.org/0000-0001-5344-6645
Omid HamidThe Angeles Clinic and Research Institute, Los Angeles, CA, USA.
Rene GonzalezUniversity of Colorado Cancer Center, Aurora, CO, USA.
Jeffrey R InfanteSarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA.
Manish R PatelSarah Cannon Research Institute/Florida Cancer Specialists & Research Institute, Sarasota, FL, USA.
F Stephen HodiDana-Farber Cancer Institute, Boston, MA, USA.
Karl D LewisUniversity of Colorado Cancer Center, Aurora, CO, USA.
Hussein A TawbiMD Anderson Cancer Center, Houston, TX, USA.
Genevive HernandezGenentech, Inc., South San Francisco, CA, USA.
Matthew J WongchenkoGenentech, Inc., South San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-1230-7117
YiMeng ChangGenentech, Inc., South San Francisco, CA, USA.
Louise RobertsGenentech, Inc., South San Francisco, CA, USA.
Marcus BallingerGenentech, Inc., South San Francisco, CA, USA.
Yibing YanGenentech, Inc., South San Francisco, CA, USA.
Edward ChaGenentech, Inc., South San Francisco, CA, USA.
Patrick HwuMD Anderson Cancer Center, Houston, TX, USA.
Sarah Cannon · USThe University of Texas MD Anderson Cancer Center · USUniversity of Colorado Cancer Center · USAngeles Clinic and Research Institute · USDana-Farber Cancer Institute · USMassachusetts General Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma treatment has progressed in the past decade with the development and approval of immune checkpoint inhibitors targeting programmed death 1 (PD-1) or its ligand (PD-L1) and cytotoxic T lymphocyte-associated antigen 4, as well as small molecule inhibitors of BRAF and/or MEK for the subgroup of patients with BRAF

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsAzetidinesB7-H1 AntigenCohort StudiesHumansKaplan-Meier EstimateMAP Kinase Kinase KinasesMelanomaMutationPiperidinesProgression-Free SurvivalProtein Kinase InhibitorsProto-Oncogene Proteins B-rafAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalatezolizumabAzetidinesB7-H1 AntigenBRAF protein, humanCD274 protein, humancobimetinibMAP Kinase Kinase KinasesPiperidinesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafVemurafenib

Identifiers

PMID31171876
OpenAlexW2948716731

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.